van Gisbergen MW, Cebula M, Zhang J, Ottosson-Wadlund A, Dubois L, Lambin P, et al
The gap between effective and ineffective use comes down to understanding that the dihexa half life dictates dosing frequency, but therapeutic outcomes are determined by what happens at the synaptic level during those brief exposure windows
165 The long-term extension of the RHAPSODY study further demonstrated that the continued use of rilonacept reduced the risk of recurrence without increasing adverse effects
and (5) outcomesreported at least one outcome we interest, including liver function tests (AST, ALT, -GT), lipid profile tests (HDL cholesterol, LDL cholesterol, total cholesterol, triglyceride), body indicators (BMI, weight, waist circumference), inflammatory factors (hs-CRP), and adverse events